Skip to main content
Caplight Logo









intoDNA

intoDNA

Private
PolandHealthcare & Life Scienceshttps://intodna.com/

Last Round

Angel

Jan 12, 2026

Total Funding Raised

$1.74M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

intoDNA is a biotechnology company that provides DNA damage detection services and diagnostic insights for pharmaceutical and clinical research using its proprietary STRIDE platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

DNA damageDNA repairprecision medicinebiomarker discoverydrug discoveryhomologous recombination deficiencyHRDDNA damage responseDDRcompanion diagnosticCDxdigital pathologyassay developmentoncology researchbiotech CROsingle-cell analysislab services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

intoDNA Comparables

Compare intoDNA with similar companies based on industry and business-model similarity.

intoDNA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Scantox Group
78%
Toxys
72%
Cellomatics Biosciences
68%

intoDNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AngelJan 12, 2026
GrantDec 9, 2024
GrantDec 20, 2021

Key People

Founding team and executive leadership

Magda Kordon

CEO, Founder

Founding Team

Kamil Solarczyk

CTO

Executive Team

Agata Wierzbicka

Chief Operating Officer

Executive Team

intoDNA Investors

Notable investors and investment history

intoDNA investors
InvestorRounds
SMOK AngelsAngel
SMOK VenturesAngel
Polish Agency for Enterprise DevelopmentGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 163% MoM.

  • May 18, 2026

    Monthly visitors increased 67% MoM, reaching 2.9K.

intoDNA Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

intoDNA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about intoDNA's valuation, stock price, and market status.

Firmographic Details

HeadquartersPoland
Employee Range46
Year Founded2017
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?